What steps should be taken for an 80‑year‑old patient who lost her recent zolpidem (Ambien) refill?

Management of Lost Zolpidem in an Elderly Patient

Do not provide an early refill for this patient; instead, use this as an opportunity to discontinue zolpidem and transition to safer alternatives, as zolpidem poses significant risks in patients over 80 years old including falls, cognitive impairment, and complex sleep behaviors. 1, 2

Immediate Clinical Response

Address the Lost Medication Claim

• Evaluate for potential misuse or diversion before considering any replacement, as zolpidem carries abuse and dependence risks that increase with duration of treatment 2
• Document the reported loss carefully and review the patient's prescription history for patterns of early refill requests or "lost" medications 2
• Explain that early refills for controlled substances like zolpidem are generally not provided due to regulatory concerns and safety considerations 2

Assess Current Sleep and Safety Status

• Determine if the patient is experiencing rebound insomnia, which can occur after abrupt zolpidem discontinuation with sleep onset latency increasing by approximately 13 minutes on the first night 3
• Evaluate for fall risk, as elderly patients on zolpidem have an odds ratio of 4.28 for falls and a relative risk of 1.92 for hip fractures 3
• Screen for complex sleep behaviors (sleep-walking, sleep-driving, preparing food while asleep) which can occur at any dose and may result in serious injury or death 2

Deprescribing Strategy

Why Discontinuation is Appropriate Now

• Elderly patients (80+ years) should receive only 6.25 mg doses if zolpidem is used at all, and the medication should be avoided when possible 2
• The 2021 Mayo Clinic guidelines explicitly list "benzo-like GABA receptor hypnotics: zolpidem, zaleplon" under medications to avoid in older adults due to sedation, cognitive impairment, unsafe mobility with injurious falls, and habituation 1
• Treatment duration should be as short as possible, and extended treatment requires re-evaluation of the patient's status since risk of abuse and dependence increases with duration 2

Gradual Discontinuation Protocol

• Implement a dose reduction of 10-25% per week if the patient has been on zolpidem chronically to minimize withdrawal symptoms including potential seizures (reported at doses as low as 160 mg/day cumulative) 3, 4
• Monitor for withdrawal symptoms including fatigue, nausea, nervousness, stomach cramps, and in rare cases, seizures 2, 3
• Reassure the patient that while mild rebound insomnia may occur initially, this typically resolves within days 3

Alternative Treatment Options

First-Line Non-Pharmacologic Approach

• Provide cognitive behavioral therapy for insomnia (CBT-I) as the gold-standard first-line treatment, which can be delivered via self-help book format with demonstrated efficacy in reducing hypnotic use 5, 4
• A 2026 study showed that a CBT-I self-help book reduced daily hypnotic use from 25.4% to 18.6% while also decreasing anxiety symptoms 5
• CBT-I has been shown to facilitate gradual discontinuation of hypnotics within cross-tapered programs 4

Safer Pharmacologic Alternatives if Needed

• Melatonin 2 mg prolonged-release is recommended by European guidelines and does not require special switching or deprescribing protocols, making it a safer option for elderly patients 4
• Daridorexant (dual orexin receptor antagonist) is another guideline-recommended option that facilitates discontinuation of benzodiazepines/Z-drugs and does not require special deprescribing protocols 4
• Low-dose doxepin or trazodone may be considered as alternatives, though these also require careful monitoring in elderly patients 6

Critical Safety Considerations

Age-Specific Risks in Octogenarians

• While one Japanese study suggested low-dose zolpidem (≤5 mg) may be "safely" prescribed to patients 80+ without cognitive complications, this study showed subjects 80+ were actually prescribed significantly lower doses and had lower adverse event rates precisely because of heightened caution 7
• Zolpidem clearance is reduced in elderly patients, particularly those with hepatic impairment, necessitating dose reduction to 6.25 mg if the medication must be continued 2, 8
• The terminal elimination half-life ranges from 1.5-3.2 hours in younger adults but is prolonged in the very elderly 8

Monitoring for Serious Adverse Effects

• CNS depression and next-day impairment can occur even at recommended doses and may not be detected by routine clinical examination 2
• Patients are at higher risk if taking other CNS depressants, have less than 7-8 hours for sleep, or have hepatic impairment 2
• Complex sleep behaviors have been reported with zolpidem alone at recommended doses and warrant immediate discontinuation if they occur 2

Documentation and Follow-Up

• Document the discussion about not replacing the lost medication and the rationale for deprescribing 1
• Schedule follow-up within 1-2 weeks to assess sleep quality, withdrawal symptoms, and response to alternative interventions 4
• Reassess after 7-10 days, as failure of insomnia to remit may indicate an underlying psychiatric or medical disorder requiring evaluation 2